BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Genetown

  Galecto to Participate at Upcoming Investor Conferences - Feb 07, 2022

  Galecto, Inc., a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced that management will be participating virtually at two upcoming conferences.

  February 7, 2022

   · 

  1 min read
• FDA

  NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

  NGM Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3, for the treatment of patients with geographic atrophy.

  February 7, 2022

   · 

  8 min read
• Business

  ORYZON Reports Results and Corporate Update for Q4 and Year Ended December 31, 2021

  Oryzon Genomics, S.A. today reported financial results for the fourth quarter of 2021 and provided an update on recent developments.

  February 7, 2022

   · 

  14 min read
• Kazia Therapeutics To Present At BIO CEO Conference

  Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the BIO CEO Conference, to be held in person and virtually in New York, NY, from 14-17 February 2022.

  February 7, 2022

   · 

  2 min read
• BioCapital

  KeifeRx to Present at 2022 BIO CEO & Investor Conference

  KeifeRx, LLC, an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative diseases, announced that its Chief Executive Officer, Chris Hoyt, will present at the 2022 BIO CEO & Investor Conference.

  February 7, 2022

   · 

  2 min read
• Business

  MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments

  MEI Pharma, Inc. today announced the expansion of its management team with the addition of two experienced industry executives.

  February 7, 2022

   · 

  5 min read
• Biotech Beach

  Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline

  Endeavor BioMedicines today announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners.

  February 7, 2022

   · 

  5 min read
• Business

  Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2021 Financial Results and Host Webcast on March 1, 2022

  Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its fourth-quarter and full-year 2021 financial results on Tuesday, March 1, 2022.

  February 7, 2022

   · 

  1 min read
• Business

  Twist Bioscience and Eleven Therapeutics Create Replicon for Development of Antiviral Tools

  Twist Bioscience Corporation and Eleven Therapeutics today announced that they have created a replicon tool that could be used for studying viral genome replication and antiviral drug screening as well as vaccine and therapeutic development.

  February 7, 2022

   · 

  5 min read
• Business

  Eyenovia Announces Changes to Board of Directors

  Eyenovia, Inc. today announced changes to its Board of Directors.

  February 7, 2022

   · 

  5 min read